Company Overview and News

0
KLCI reverses loss but broader sentiment stays tepid

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): The FBM KLCI reversed its earlier losses at the midday break today, lifted by select index-linked blue chips, but the broader market sentiment remained tepid, tracking regional markets.
7083 HLFBF 1082 5032 NFLX BATS 4162 3794 9334 6033 7277 2852 PNADF 5225 3301 3867 4723 Q0F IHHHF 6807 PNAGF 1929

0
KLCI pares loss but seen staying in the red, tracking region

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): The FBM KLCI pared some of its losses at mid-morning today but looked poised to end the session in the red as regional markets remained weak.
7083 6491 7251 7060 4065 BC94 SMSN BATS 4162 7237 3034 3794 9334 6033 7123 2852 PNADF 3867 6807 PNAGF SMSD

0
Analabs proposes one-for-one bonus issue

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): Analabs Resources Bhd has proposed to undertake a bonus issuance on the basis of one bonus share for every existing share held, the group said today.
7083

0
KLCI rises 0.56% as banking heavyweights lift

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI rose 0.56% at mid-morning today, boosted by gains including at index-linked banking heavyweights.
PBLOF 7251 MLYNF 1295 7153 3794 2089 5014 9334 3867 6459 CSX MS 7083 MLYBY UPBMF 0170 0131 7123 1155 4588 MYPRY

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...